Quantum BioPharma is trading 5% down at $3.40, with broader market pressure potentially contributing.

  • The previous session saw an 8.81% gain to $3.58.
  • No new company-specific announcement was identified for September 10, 2026; the latest major catalyst remains FDA clearance for a Phase 2 Lucid-MS trial, reported September 9.
  • Nasdaq futures are down 0.70% as investors await inflation data and assess elevated oil prices.